These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10409825)

  • 1. Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system.
    Dominy BN; Brooks CL
    Proteins; 1999 Aug; 36(3):318-31. PubMed ID: 10409825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
    Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
    Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
    J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
    Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
    J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
    Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
    Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
    Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
    Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling of the structure of FIV protease.
    Gustchina A
    Adv Exp Med Biol; 1995; 362():479-84. PubMed ID: 8540361
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
    Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
    Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.
    Kervinen J; Lubkowski J; Zdanov A; Bhatt D; Dunn BM; Hui KY; Powell DJ; Kay J; Wlodawer A; Gustchina A
    Protein Sci; 1998 Nov; 7(11):2314-23. PubMed ID: 9827997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
    Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
    Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
    Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
    Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
    Lin YC; Perryman AL; Olson AJ; Torbett BE; Elder JH; Stout CD
    Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):540-8. PubMed ID: 21636894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
    Beck ZQ; Lin YC; Elder JH
    J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking the shackles of the genetic code: engineering retroviral proteases through total chemical synthesis.
    Kent SB; Baca M; Elder J; Miller M; Milton R; Milton S; Rao JK; Schnölzer M
    Adv Exp Med Biol; 1995; 362():425-38. PubMed ID: 8540353
    [No Abstract]   [Full Text] [Related]  

  • 17. Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
    Lin YC; Torbett BE; Elder JH
    J Virol; 2010 Jul; 84(13):6799-809. PubMed ID: 20410281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mean field model of ligand-protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor-specific binding.
    Verkhivker GM; Rejto PA
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):60-4. PubMed ID: 8552675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding.
    Kalra P; Reddy TV; Jayaram B
    J Med Chem; 2001 Dec; 44(25):4325-38. PubMed ID: 11728180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
    Chen Z; Li Y; Chen E; Hall DL; Darke PL; Culberson C; Shafer JA; Kuo LC
    J Biol Chem; 1994 Oct; 269(42):26344-8. PubMed ID: 7929352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.